Fulminant rebound of relapsing–remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report

Abstract

Background:

Rebound phenomena after discontinuation of different treatments for relapsing–remitting multiple sclerosis (RRMS) have previously been described. Systematic database research in PubMed did not show any report with relapse directly associated with dimethyl fumarate (DMF) cessation.

Case presentation:

Here, we report on a 38-year-old Caucasian male patient suffering from a relatively mild course of RRMS who developed a fulminant clinical rebound 2 months after discontinuation of DMF therapy. Radiological alterations presented impressively with primarily spinal involvement. The patient received intensive care and multiple immunomodulating therapies.

Conclusion:

We report on this case to raise neurologist’s awareness of complications of basic therapy discontinuation in RRMS.

Keywords

Multiple sclerosis dimethyl fumarate discontinuation dimethyl fumarate cessation clinical rebound

Get full access to this article

View all access options for this article.

References

Chen

Assmann

Krenz

et al . Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest 2014; 124(5): 2188–2192.

Altmeyer

Matthes

Pawlak

et al . Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30(6): 977–981.

Bomprezzi

Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: An overview. Ther Adv Neurol Disord 2015; 8(1): 20–30.

De Masi

Accoto

Orlando

et al . Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption. BMC Neurol 2015; 15: 125.

Hatcher

Waubant

Nourbakhsh

et al . Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 2016; 73(7): 790–794.

Gündüz

Kürtüncü

Eraksoy

Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis. Mult Scler Relat Disord 2017; 11: 1–3.

Verhaeghe

Deryck

Vanopdenbosch

LJ.

Pseudotumoral rebound of multiple sclerosis in a pregnant patient after stopping natalizumab. Mult Scler Relat Disord 2014; 3(2): 279–281.

Larochelle

Metz

Lecuyer

et al . Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Mult Scler J 2017; 23(1): 72–81.

Zamvil

Slavin

AJ.

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Neurol Neuroimmunol Neuroinflamm 2015; 2(1): e62.

10.

Wingerchuk

Banwell

Bennett

et al . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85(2): 177–189.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.50 MB